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Abstract
Background
Defensins play an important role in the processes associated with innate immunity.
Their  growth  is  observed  in  sites  of  intense  inflammation,  but  also  in  less  severe
inflammation. Evaluation of alpha-defensin levels in patients with chronic heart failure (CHF)
and its possible association with a long-term prognosis may be an interesting supplement to
knowledge about the state of the immune system in heart failure.
422
The aim of  the  study was to  compare  the  plasma concentration  of  alpha-defensin
between the patients  with chronic heart  failure with impaired ventricular  ejection  fraction
(LVEF) <45% and the control group, as well as to evaluate the prognostic value of alpha-
defensin as a possible predictor of death during a 24-month observation period.
Methods 
The study included 52 hospitalized  patients  with a  primary diagnosis  of  CHF and
LVEF <45%. 20 patients  exhibited  features  of CHF exacerbation,  the remaining 32 were
hospitalized  on  schedule.  The  control  group  consisted  of  28  healthy  volunteers.  The
observation was conducted by telephone for 2 years. The end point of the study was death for
all reasons.
Results 
Patients  with  CHF  had  significantly  higher  levels  of  alpha-defensin  than  control
subjects. Similarly, plasma hs-CRP levels were significantly higher in the study group than in
the control group, although in both groups the median hs-CRP did not exceed 5 mg / L. It has
not been shown that exacerbation has an effect on alpha-defensin concentration. During the
two-year  follow-up,  statistically  significant  effects  on  the  endpoint  of  the  following
parameters were observed: EF (p = 0.035, HR = 0.917), hs-CRP (p = 0.036; HR = 1.046) and
NT-proBNP (p < 0.001, HR = 1.000078). ROC analysis showed that during both a 12-month
(AUC = 0.333, p = 0.116) as well as a 24 month (AUC = 0.447, p = 0.616) observation period
plasma concentration of alpha-defensin was not a good predictor of death in CHF patients.
Conclusions
Higher  levels  of  alpha-defensin  in  patients  with  CHF  confirm  subclinical
inflammatory activation in this population. However, this marker does not have predictive
value for predicting death in the medium-term observation.
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Background
The price of the success of modern cardiology in the field of treatment of coronary
heart disease is steadily increasing incidence of heart failure. Rapid and accurate diagnosis of
patients with chronic heart failure (CHF) is extremely important both in clinical and economic
terms. Finding new useful biomarkers in the diagnosis and risk stratification of patients with
heart failure is, therefore, a matter of utmost importance.
Chronic  heart  failure  (CHF)  is  a  disease  in  which  irrespective  of  etiology,
proinflammatory activation is associated with chronic tissue ischemia, oxidative stress, and
stimulation  of  hormonal  compensatory  mechanisms  (adrenergic,  RAA).  Inflammation  of
minor  severity  is  inherently  accompanied  by  heart  failure  and,  just  as  in  ischemic  heart
disease,  diabetes  or  renal  failure,  its  intensity  (measured  most often  by plasma c-reactive
protein levels) is an important deterioration factor. The position of the C-reactive protein in
cardiology  indicates  the  potential  associated  with  the  assessment  of  inflammation  in
cardiovascular diseases, particularly in chronic heart failure [1-4].
Defensins are substances that play an important role in the processes associated with
congenital resistance, their growth is observed in places of intense inflammation but also in
less severe inflammatory conditions. Evaluation of alpha-defensin levels in patients with CHF
and its possible association with long-term prognosis may be an interesting addition to the
knowledge about  the condition  of  the  immune  system in HF,  and at  the  same time  may
become a valuable part of the treatment of these patients.
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The aim of  the  study was to  compare  the  plasma concentration  of  alpha-defensin
between the population of CHF patients with impaired left ventricular ejection fraction and
the  control  group,  and  to  evaluate  the  prognostic  value  of  alpha-defensin  as  a  possible
predictor of death during a 24-month observation period.
Methods
The study group consisted of 52 Caucasian patients hospitalized in the II Clinic of
Cardiology CM UMK with diagnosed CHF NYHA classes II-IV (20 patients) or for planned
medical procedures (32 patients). All patients received optimal pharmacological treatment in
accordance with the guidelines of the European Society of Cardiology. The inclusion criteria
in the study included: age over 18 years, HF with impaired left ventricular ejection fraction
(LVEF) <45% assessed during current hospitalization or up to 6 months earlier. The exclusion
criteria  in  the  study  were:  acute  coronary  syndrome,  acute  heart  failure,  severe  renal
impairment  (GFR <30ml /  min),  active tumor disease,  active infection,  fever of unknown
etiology,  autoimmune  disease,  corticosteroid  therapy,  decompensated  diabetes  requiring
intravenous infusion of insulin, chronic obstructive pulmonary disease, substitution therapy
with iron preparations and chronic inflammatory bowel disease.
On admission  to  hospital  all  patients  in  the study group received peripheral  blood
morphology,  creatinine  concentration,  ion  concentration,  iron  concentration,  LDL,  HDL,
plasma concentration  of  high-sensitivity  C-reactive  protein  with  turbidimetry  method (hs-
CRP),  plasma  Ferritin  concentration  and  plasma  concentration  of  natriuretic  N-terminal
natriuretic propeptide (NT-proBNP). In addition, a blood sample was also collected from each
patient,  which  was  then  stored  at  -80  °  C  until  the  alpha-defensin  concentration  was
determined, within a period not exceeding 3 months. A commercially available ELISA kit
(USCN Life Science, code no. SEB 705Hu) was used to determine the plasma level of alfa-
defensin. The observation was conducted by telephone - every 3 months since the inclusion in
the study telephone contact  took place,  during which the appearance of the endpoint was
evaluated. The endpoint of the study was death for all causes in a 24-month follow-up. The
control group consisted of 28 healthy volunteers.
The results  were analyzed using Statistica ver. 12. The probability of p <0.05 was
statistically  significant.  The  normality  of  the  analyzed  parameters  was  checked  with  the
Shapiro-Wilk  test.  In  the  absence  of  normal  distributions,  nonparametric  analyzes  were
performed. Plasma concentration of alpha-defensin, Hs-CRP, ferritin, NT-proBNP, troponin T
heart (TnT), iron, hemoglobin (Hb), HDL, LDL, BMI, LVEF were compared in total  and
depending on the occurrence of death in the-24 month observation using the Mann-Whitney
test. NYHA class, sex, age, diabetes, GFR and etiology were compared using the χ 2 and χ 2
tests with the Yates correction. Evaluation of the diagnostic power of the alpha-defensin test
in predicting death during a 24-month follow-up was based on ROC (ROC) analysis. Analysis
of correlation between alpha-defensin, hs-CRP, ferritin, NT-proBNP, TnT, Hb, class NYHA
and EF was performed to estimate Spearman rank correlation coefficients. A comparison of
individual parameters between the study and the control group as well as between the patients
with exacerbation of CHF and stable patients was performed with the Mann-Whitney test.
The  relative  risk  (HR)  of  the  markers  was  calculated  on  the  basis  of  univariate  and
multivariate  COX regression.  The  comparison  of  plasma  concentration  of  alpha-defensin
between patients classified in NYHA class II and patients classified in NYHA class III or IV
was performed using the Mann-Whitney test.
Results
The study included 52 patients with CHF with impaired LVEF whose mean age was
60 ± 13 years; male accounted for 86.5% of all patients; 32 patients were in stable clinical
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condition; CHF exacerbation syndromes occurred in 20 patients. The clinical and laboratory
characteristics of the study group are shown in Table 1. During the two-year follow-up period,
14 patients (26.92%) died. Patients who died had significantly statistically lower LVEF and
higher plasma concentrations of troponin T and NT-proBNP. The control group consisted of
28 healthy volunteers whose average age was 50 ± 7 years and male accounted for 39.3% of
the volunteers.
Patients  with  CHF  had  significantly  higher  concentration  of  alpha-defensin  than
patients  in  the  control  group  (Table  2).  Similarly,  the  plasma  level  of  hs-CRP  was
significantly higher in the study group than in the control group, although in both groups the
median  hs-CRP  did  not  exceed  5  mg  /  l.  In  the  study  group  between  patients  with
exacerbation of CHF and clinically stable patients there was no significant difference in the
alpha-defensin concentration and no difference in overall mortality during both one-year and
the two-year follow-up (Table 3).
Table 1. Basic characteristics of the studied population, depending on the occurrence of the
endpoint.
The variable Total number (n=52) Survial (n=38; 73,08%) Death (n=14; 26,92%) p 
Age (years)* 59,81±12,72 58,71±13,14 62,79±11,42 0,6425
Men 86,54% 86,84% 85,71% 0,9158
Ischemic etiology 48,08% 52,63% 37,71 0,2788
BMI (kg/m2)* 28,36±5,22 28,28±5,45 28,57±4,74 0,7491
NYHA class II/III/IV 26,92%/61,54%/11,54% 34,21%/55,26%/10,53% 7,14%/78,57%/14,29% 0,1486
DM 38,46% 36,84% 42,86% 0,6925
EF (%)* 27,04±8,11 28,61±8,28 22,786±6,03 0,0273
GFR <60 / >60 (%) 44,23%/55,77% 36,84%/63,16% 64,29%/35,71% 07716
Hb (g/dl)** 14,15 (13,05-15,10) 14,20 (13,20-15,10) 13,92 (12,20-15,00) 0,6499
Fe (μg/dlg/dl)** 68,50 (53,00-91,50) 74,50 (54,00-96,00) 61,00 (46,00-76,00) 0,3121
Alfa-defensin (ng/ml)** 175,46 (159,62-187,54) 176,85 (164,34-186,32) 165,48 (135,90-190,76) 0,5705
hs-CRP (mg/L)** 4,08 (1,82-8,32) 3,67 (1,68-7,37) 6,02 (3,82-13,80) 0,0968
Ferritin(μg/dlg/dl)** 138,00 (86,50-224,00)  141,00 (88,00-223,00) 127,00 (78,00-241,00) 0,6499
TnT (µg/l) ** 0,020 (0,014-0,036) 0,019 (0,013-0,030) 0,035 (0,020-0,048) 0,0137
NT-proBNP (pg/ml)** 1179 (697-4297) 1017 (566-2229) 4521,5 (1169-6702) 0,0006
LDL (mg/dl)** 101,5  (79-133,5) 101,5 (80-127) 111 (71-164) 0,5846
HDL  (mg/dl)** 38 (30,5-48,5) 40,5 (34-47) 33 (28-51) 0,3919
ACEi 78,85% 78,95% 78,57% >0,05
ARB 23,08% 21,05% 28,57% >0,05
statin 86,54% 92,11% 71,43% >0,05
beta-blocker 100% 100% 100% >0,05
ASA 48,08% 50,00% 42,86% >0,05
digoxin 32,69% 28,95% 42,86% >0,05
spironolacton 75,00% 71,05% 85,71% >0,05
eplerenon 19,23% 21,05% 14,29% >0,05
The results were presented as:
 * average ± standard deviation 
** median (bottom quartile − upper quartile)
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Age* 59,81±12,72 50,00±6,97 <0,001
Male 86,54% 39,29%













Hs-CRP (mg/L)** 4,08 (1,82-8,33) 1,00 (0,60-1,50) <0,001
The results were presented as: 
* average ± standard deviation 
** median (bottom quartile − upper quartile)
Table 3. Comparison of alpha-defensin concentration and overall mortality between patients
with CHF exacerbation and clinically stable patients.







Alfa-defensin (ng/ml)* 175 (160-188) 177 (165-188) 170 (131-188) 0,137
Mortality during 1-
year follow-up
n=10 ( 19,23%) n=4 (12,50%) n=6 (30,00%) 0,120
Mortality during 2-
year follow up
n=14 ( 26,92%)        n=8 (25,00%) n=6 (30,00%) 0,581
The results were presented as: 
* median (bottom quartile − upper quartile) 
n − numbers of patients
Univariate  Cox-propotional  hazard  analysis  during the 1-year  follow-up showed that  only
plasma concentration of NT-proBNP (p <0.001; HR = 1) significantly statistically affected the
occurrence  of  the  endpoint  (Table  4),  whereas  during  the  2-year  follow-up  statistically
significant effects on the endpoint of the following parameters were observed: LVEF (p =
0.035; HR = 0.917), hs-CRP (p = 0.036; HR = 1.046) and NT-proBNP (p <0.001; HR = 1)
(Table 5).
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Table  4.  Univariate  Cox-propotional  hazard  analysis  –  1-year  follow-up;  statistically
significant correlations are presented in bold (p < 0.05).
- p HR
(-95%; 95% confidence interval for
HR)
Age 0,115 0,185 (0,99; 1,10)
Sex 0,506 0,591 (0,13; 2,78)
BMI 0,845 1,012 (0,90; 1,14)
HF etiology 0,879 0,908 (0,26; 3,14)
Diabetes 0,879 0,608 (0,18; 2,10)
NYHA          0,432 0,608 (0,18; 2,10)
EF 0,092 0,921 (0,84; 1,01)
Hb 0,371 0,820 (0,53; 1,27)
Alfa-defensin 0,076 0,985 (0,97; 1,00)
NT-proBNP <0,001 1,00019 (1,000097; 1,000282)
hs-CRP 0,417 1,026 (0,96; 1,09)
Ferritin 0,642 0,999 (0,995; 1,003)
TnT 0,185 1187,918 (0,03; 42226303)
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Table  5.  Univariate  Cox-propotional  hazard  analysis  –  2-year  follow-up;  statistically
significant correlations are presented in bold (p < 0.05).
- p HR
(-95%; 95% confidence interval for
HR)
Age 0,274 1,025 (0,98; 1,07)
Sex 0,861 0,875 (0,196; 3,91)
BMI 0,910 1,005 (0,91; 1,11)
HF etiology 0,358 1,670 (0,56; 4,99)
Diabetes 0,665 0,791 (0,27; 2,28)
NYHA 0,102 0,183 (0,02; 1,40)
EF 0,035 0,917 (0,85; 0,99)
Hb 0,215 0,764 (0,50; 1,17)
Alfa-defensin 0,242 0,991 (0,98;1,01)
NT-proBNP <0,001 1,000078 (1,000039; 1,000116)
hs-CRP 0,036 1,046 (1,003; 1,091)
Ferritin 0,805 1,000 (0,998; 1,002)
TnT 0,181 1182,846 (0,037; 37912315)
In multivariate analysis, both the 1-year and the 2-year follow-up showed that NT-proBNP
plasma  concentration  was  the  only  independent  statistically  significant  factor  affecting
mortality in the observed patient group (Table 6).
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Table 6. Multivariate Cox-propotional hazard analysis –  1-year and 2-year follow-up    
 (p < 0,05). 
- p HR









<0,001 1,000077 (1,000038; 1,000115)
The  ROC  analysis  showed  that  during  the  12-month  (AUC  =  0.333;  confidence
interval (-95%; 95%) = 0.126-0.541; p = 0.116) and the 24-month (AUC=0,447; confidence
interval  (-95%;  95%)  -  0.242-0.653;  p  =  0.616)  follow-up  plasma  concentration  of  alfa-
defensin did not appear to be a valuable prognostic factor for predicting death for all causes in
patients with CHF.
The comparison of plasma alpha-defensin concentration between patients classified in
NYHA class  II  as  well  as  in  NYHA class  III  or  IV did  not  show statitically  significant
differences in alpha-defensin concentration between these patients (p = 0.34), as shown in
Figure 1.
Figure 1. Plasma concentrations of alpha-defensin depending on NYHA class (p = 0.34). The
comparison of plasma alpha-defensin concentration between patients classified in  NYHA
class II as well as in NYHA class III and IV.
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In addition, a correlation analysis was performed between each of the prognostic markers,
estimating Spearman`s rank correlation coefficients, as shown in Table 7.
Table 7. Spearman`s rank correlation between the prognostic markers. Statistically significant
correlations are presented in bold (p < 0.05).
- CRP TnT NT-proBNP FERRYTYNA Alfa-defensyna Hb EF NYHA
CRP 1,000 0,346 0,347 -0,079 -0,258 -0,112 0,012 0,127
TnT 0,346 1,000 0,464 -0,148 -0,137 -0,099 -0,136 0,197
NT-proBNP 0,347 0,464 1,000 -0,279 -0,083 -0,144 -0,430 0,218
FERRYTIN -0,079 -0,148 -0,279 1,000 -0,128 0,384 0,103 -0,188
Alfa-defensyna -0,258 -0,137 -0,083 -0,128 1,000 0,006 0,144 0,136
Hb -0,112 -0,010 -0,144 0,384 0,006 1,000 -0,119 0,09
EF 0,0120 -0,136 -0,430 0,103 0,144 -0,119 1,000 -0,009
NYHA 0,127 0,197 0,218 -0,188 0,136 0,09 -0,009 1,000
Discussion
Defensins are small (3-5 kDa) antimicrobial peptides with a β-harmonica structure. In
their structure defensins usually contain six cysteine residues linked by three disulfide bonds.
They are conventionally divided into: α-, β-, θ-defensins. Human alpha-defensins (6 of them
have  been  carefully  characterized)  HNP-1,2,3,4  (human  neutrophil  alpha-defensins)  are
produced in neutrophil granulocytes and HD-5,6 defensins (human defensins) in Panetha cells
and epithelial cells in female reproductive tract [1-4]. Every day the human body produces 2 ×
109 neutrophils / kg of body weight, which translates to 10 mg of defensins in this mass unit.
Human genes for defensin alpha are mainly located in the 8p23.1 chromosome (10% of the
population  does  not  have  HNP3  defensin  gene)  [5].  Defensins  are  one  of  the  most
conservative, oldest phylogenetic elements of the immune system. They belong to the family
of antimicrobial proteins (AMP - antimicrobial proteins), having antimicrobial, antiparasitic,
antiviral  and antifungal properties.  Alpha-defensin concentration increases in inflammation
sites, and in serum - in systemic infections. This increase in plasma defensives occurs 2-4
hours after contact with the triggering agent. Patients with lack of defenses due to neutrophil
granulomas (SDG) are more likely to suffer from acute bacterial  infections [6]. Defensins
activate mast cells leading to their degranulation, the release of histamine and prostaglandin
D2, which are known mediators of inflammation.  These peptides may further increase the
production of tumor necrosis factor (TNF) and interleukin-1 (IL-1), and reduce the production
of  anti-inflammatory  interleukin  10  (IL-10)  [7,8].  Alpha-defensins  act  chemotactically  on
CD8 T lymphocytes, immature dendritic cells, and immature T lymphocytes, enhancing or
suppressing activation of the classical complement pathway [9,10].
So far, the impact of alpha-defensin on the cardiovascular system has been assessed in
relatively  small  studies.  Alpha-defensin  promotes  the  accumulation  of  lipoprotein  (a)
significantly  contributing  to  the  formation  of  foam  cells,  endothelial  dysfunction  and
atherosclerotic plaque development [11-13]. The presence of elevated concentrations of this
peptide as a manifestation of inflammatory processes has been observed in atherosclerotic
plaques  [14-16].  Nassar  and  co-authors  also  showed  that  elevated  alpha-defensin
concentration  in  skin  biopaths  is  an  independent  factor  that  determines  the  severity  of
coronary artery disease observed during coronary angiography [16]. Elevated alpha-defensin
levels are observed in Behcet's disease, and patients with type 1 diabetes with higher alpha-
defensin  concentration  have  a  higher  incidence  of  cardiovascular  disease  and  higher
cardiovascular mortality. In addition, significantly higher levels of this peptide were observed
in diabetic nephropathy and accompanying albuminuria [17,18].
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CHF  is  characterized  by  increased  activity  of  the  immune  system  and  chronic
inflammation,  which  results  in  an  increase  in  the  concentration  of  a  number  of
proinflammatory  cytokines,  chemokines  and  adhesion  molecules.  The  precise  mechanism
leading to these changes is unknown, but at present significant importance is attributed to
unfavorable haemodynamic changes, oxidative stress, toll-like receptor hyperactivity (TLR),
molecular mimicry and chronic immune system stimulation by bacterial antigens, and gastric
endotoxin  extrusion.  Changing  the  ratio  of  proinflammatory  factors  -  anti-inflammatory
factors  not  only  leads  to  the  development  and  progression  of  CHF,  but  also  to  the
deterioration of the function of other organs, which is associated with worse prognosis of
patients with CHF [19-21]. The first study that showed a relationship between inflammatory
intensity expressed by elevated CRP and clinical deterioration in patients with CHF was the
study by Elster and co-authors. [22].
Our study was conducted among patients of the Polish population who belong to the
high risk population, as confirmed by two large epidemiological studies - NATPOL PLUS
and  WOBASZ.  The  NATPOL  PLUS  study  (n  =  2399)  showed  that  our  country  was
characterized  by  high  CRP levels  -  mean  hs-CRP was  2.03  ±  2.14  mg  /  l  [23].  In  the
WOBASZ study (n = 6561) it amounted to 2.7 ± 4.8 mg / l [24]. For comparison, in highly
developed European countries as well as in Japan, CRP is significantly lower [25,26]. In this
study, the median of CRP plasma, in patients with chronic severe disease, is undoubtedly
relatively low for HF, which is most likely due to numerous exclusion criteria for patients
with chronic inflammation of differentiated etiology.
All the more important is the observation of elevated alpha-defensin levels in patients
with chronic heart failure. In our opinion, the observed phenomenon indicates the presence of
inflammation in patients with CHF even at low CRP values. This is confirmed by numerous
reports of the existence of proinflammatory stimulation resulting from many of the processes
involved  in  the  development  of  CHF,  including  hypoxia,  oxidative  stress  or  bacterial
antigenic stimulation. The results of this study may point to the need to assess inflammation
in this group of patients, and possibly other cardiovascular disease patients, using other, more
sensitive inflammatory markers, or a set of markers.
According to our knowledge, this is the second study in the world that evaluates the
prognostic value of alpha-defensin in patients with CHF. The results of our study indicate that
alpha-defensin  has  no  prognostic  value  in  this  group  of  patients.  Christensen  et  al.  [27]
demonstrated significant prognostic value of alpha-defensin in CHF patients. However, the
data analysis presented in our study is not an exact replicate of the analysis by Christensen et
al.  On the basis  of the alpha-defensin concentration  the quoted authors divided the study
group  into  quartiles.  Moreover,  logarithmic  transformations  were  used  to  present  alpha-
defensin concentration, and thus the statistics can be ambiguous. In the study by Christensen
et al.,  there was no significant  difference between the alpha-defensin concentration in the
study group and the control group: 496 (307-685) mg / L vs. 486 (348-624) mg / l, p = 0.25,
significant differences were observed with clinical deterioration: NYHA III-IV 599 (368-830)
mg  /  L  vs.  NYHA  I-II  486  (317-655)  mg  /  l,  p  =  0.002),  which  also  creates  some
interpretation difficulties and raises doubts as to the fairness of such data presentation.
Patients in our study were characterized by lower values of  LVEF. Moreover, patients
classified in NYHA class III and IV represented the majority of all patients that participated in
the study, which may also affect the results. The pharmacological therapy used in patients in
the study by Christensen et al. may also raise doubts, where in subsequent terciles β-blocker
took 33.5 / 30.2 / 29.7% of the patients, whereas ACEi / Sartan sequentially 72.3 / 87.3 /
431
67.7% of the patients. In our study, 100% of the study group received β-blocker and ACEi /
sartan.
Christensen et al. did not took into account any exclusion criteria while pereparing
their study, and thus, it cannot be ruled out that the factor that significantly influenced the
prognosis of patients was chronic inflammation resulting not from CHF, but from other co-
morbid conditions. Higher alpha-defensin levels reflect inflammation that may have had an
effect on prognosis, but the liberal selection of the group may have influenced the results and
conclusions received.
We  also  did  not  see  higher  alpha-defensin  concentration  in  patients  with  more
advanced heart failure or in patients admitted with exacerbation. It seems that the causes of
such a marker breakdown may lie in the selection and size of the study group. First, it was a
relatively small population and, secondly, was characterized by severe left ventricular systolic
dysfunction  (mean  LVEF  27%)  and  high  clinical  homogeneity  -  more  than  60% of  the
patients were in NYHA class III.
As  expected,  the  strongest,  independent  predictor  of  death  was  the  plasma
concentration of the recognized marker - NT-proBNP, confirming the unquestionable position
of natriuretic  peptides in the prognosis process in this  group of patients.  It also indirectly
indicates  the  predominant  influence  of  increasing  haemodynamic  disturbances  on  the
prognosis  of  patients  with  heart  failure.  It  appears  that  among  patients  with  such  CHF
progression, inflammation is merely an accompanying pathology without a significant effect
on and serious prognosis.
This  study  demonstrated  that  alpha-defensin  cannot  be  a  statistically  significant
predictor of death in patients with CHF. This result, despite a fairly long observation period,
is only preliminary due to the relatively small sample size limiting the possibility of drawing
far-reaching conclusions. Our study is a pilot study, and a full assessment of the possible
prognostic value of alpha defensiveness will  undoubtedly require wider analyzes in larger
patient groups. The hope of alpha defensiveness seems to be all the more justified because
another  inflammatory  marker  -  CRP -  is  an important  prognostic  factor  in cardiovascular
disease. The value of our observations is primarily confirmed by the new marker of chronic
inflammation in a select group of heart failure patients with a relatively low CRP marker
value.  This  may  indicate  the  need  to  seek  new  markers  more  precisely  defining  pro-
inflammatory-anti-inflammatory balance in CHF populations, or suggest the need for a set of
biochemical factors that provide better insight into the clinical status of CHF patients.
Conclusions
1.  Increased  plasma concentration  of  alpha-defensin  in  patients  with  chronic  heart
failure  with  impaired  left  ventricular  ejection  fraction  confirms  subclinical  inflammatory
activation in this group despite relatively low CRP values.
2. Alpha-defensin did not prove to be a valuable predictor of death in CHF patients in
both annual and biennial observation.
3. The only significant factor for poor prognosis was NT-proBNP, which confirms the
strong position of natriuretic peptides not only in the diagnostic but also prognostic process in
CHF patients.
Study limitations
The results of this study may not refer to patients with acute HF and in patients with CHF
with left ventricular systolic function.
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